(NE)-N-(7-fluoro-2,3-dihydrochromen-4-ylidene)hydroxylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (NE)-N-(7-fluoro-2,3-dihydrochromen-4-ylidene)hydroxylamine
• 化学式: C₉H₈FNO₂
• 分子量: 181.16
• InChiKey: BNXYIHVAMFBTFE-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017222083A1

  公开（公告）日：2017-12-28

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，其中n、X1、X2、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和R13如规范中定义的那样，其制备方法，含有它们的药物组合物以及它们在治疗中的应用。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2016142867A1

  公开（公告）日：2016-09-15

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及对抗血管紧张素II型2(AT2)受体的杂环化合物。更具体地，本发明涉及公式(I)所述的化合物，包含它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病中的使用，包括神经病理性疼痛、炎症性疼痛、与神经元过敏性相关的疾病、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成不平衡相关的疾病以及与异常神经再生相关的疾病。
• [EN] USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VI<br/>[FR] UTILISATION DE COMPOSÉS DE TYPE STROBILURINE POUR LUTTER CONTRE DES CHAMPIGNONS PHYTOPATHOGÈNES, CONTENANT UNE SUBSTITUTION D'ACIDES AMINÉS F129L DANS LA PROTÉINE DU CYTOCHROME B MITOCHONDRIAL CONFÉRANT UNE RÉSISTANCE À DES INHIBITEURS DE QO VI
  申请人：BASF SE

  公开号：WO2022008303A1

  公开（公告）日：2022-01-13

  The present invention relates to the use of strobilurin type compounds of formula (I) and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

  本发明涉及使用式（I）的链霉菌类化合物及其N-氧化物和盐来对抗包含线粒体细胞色素b蛋白中氨基酸替换F129L（也称线粒体细胞色素b基因中F129L突变）的植物病原真菌，该突变使其对Qo抑制剂具有抗性，并且涉及对抗这种真菌的方法。 本发明还涉及新化合物，制备这些化合物的方法，包含至少一种这样的化合物的组合物，以及涂有至少一种这样的化合物的种子。
• P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF
  申请人：Shanghai Zhimeng Biopharma, Inc.

  公开号：EP3798220A1

  公开（公告）日：2021-03-31

  The present invention relates to a p-phenylenediamine derivative as a potassium channel regulator and a preparation method and medical application thereof. In particular, disclosed is a compound represented by general formula A or a pharmaceutically acceptable salt thereof. Also disclosed are a preparation method of the compound and a use of the same as a potassium channel opener.

  本发明涉及一种作为钾通道调节剂的对苯二胺衍生物及其制备方法和医疗应用。特别是公开了通式 A 所代表的化合物或其药学上可接受的盐。还公开了该化合物的制备方法及其作为钾通道开放剂的用途。